Every 8-K that Pacira BioSciences, Inc. (PCRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PCRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCRX filings page.
Pacira BioSciences reported second quarter 2026 total revenue of $192.4 million, up 6% from $181.1 million a year earlier, led by EXPAREL sales of $147.8 million and ZILRETTA sales of $32.6 million. GAAP net income was $4.7 million, or $0.12 per share, compared with a $4.8 million loss in 2025. Non-GAAP net income was $29.5 million and adjusted EBITDA $48.7 million, both below prior-year levels.
The company completed the divestiture of its iovera° business to Zimmer Biomet for up to $140 million, receiving $73.6 million in cash at closing, and ended the quarter with $251.0 million in cash, cash equivalents and investments. Updated 2026 guidance calls for total revenue of $735–$760 million, including EXPAREL sales of $600–$620 million, non-GAAP gross margin of 77–79%, and lower non-GAAP SG&A expense of $310–$330 million. Pacira also highlighted expanded reimbursement for EXPAREL from UnitedHealthcare and continued clinical progress for its gene therapy candidate PCRX-201.
Pacira BioSciences agreed to divest its iovera° handheld cryoanalgesia device business to Zimmer Biomet for up to $140.0 million, consisting of an upfront $70.0 million payment and up to an additional $70.0 million in revenue-based milestones through December 31, 2031.
Milestones pay out in tranches of $18.5 million, $23.5 million or $28.0 million if annual iovera° net revenue reaches $50.0 million, $60.0 million or $70.0 million in any year from 2027 to 2031. About 66 employees, roughly 8% of Pacira’s workforce, are expected to join Zimmer Biomet.
Pacira plans to use upfront net proceeds to strengthen its balance sheet, including paying down its senior secured revolving credit facility, and will collaborate with Zimmer Biomet on the iovera° spasticity program with potential incremental compensation. Closing is subject to customary conditions and is expected in the third quarter of 2026.
Pacira BioSciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where all three of the company’s Class III director nominees—Christopher J. Christie, Samit Hirawat and Thomas Wiggans—were elected to the board over an opposing slate nominated by DOMA Perpetual Capital Management LLC.
Stockholders approved an amendment and restatement of the 2014 Employee Stock Purchase Plan, adding 800,000 newly reserved shares of common stock for issuance, and ratified the appointment of KPMG LLP as independent auditor for the fiscal year ending December 31, 2026. They also approved on an advisory basis the compensation of named executive officers.
The Amended and Restated 2011 Stock Incentive Plan did not receive sufficient votes for approval. As of April 22, 2026, 39,334,983 shares of common stock were outstanding and entitled to vote. Following the meeting, the board reassigned membership across its Audit, People & Compensation, and Nominating, Governance and Sustainability committees.
Pacira BioSciences reported first quarter 2026 revenue of $177.4 million, up 5% from $168.9 million a year earlier, driven by growth across its non‑opioid pain portfolio. EXPAREL sales were $143.3 million, up 5%, ZILRETTA reached $26.8 million, up 15%, and iovera° rose 21% to $6.2 million.
GAAP net income was $2.9 million, or $0.07 per share, down from $4.8 million, or $0.10 per share, reflecting higher R&D and SG&A spending. Non‑GAAP net income was $24.5 million, or $0.60 per share, versus $30.0 million a year ago, and adjusted EBITDA was $40.2 million, compared with $44.1 million.
The company ended the quarter with $202.2 million in cash, cash equivalents and available‑for‑sale investments, and repurchased 2.2 million shares for $50.0 million, leaving 39.3 million shares outstanding at March 31, 2026. Pacira completed enrollment in its Phase 3 ZILRETTA shoulder osteoarthritis study and highlighted ongoing development of gene therapy candidate PCRX‑201. Full‑year 2026 guidance was reiterated, including EXPAREL sales of $600–$620 million and total revenue of $745–$770 million, with targeted non‑GAAP gross margin of 77–79%.
Pacira BioSciences reported modest growth for 2025 and returned to profitability, while laying out guidance for 2026. Total 2025 revenue was $726.4 million, up 4% from 2024, led by EXPAREL net product sales of $575.1 million, a 5% increase.
The company posted 2025 GAAP net income of $7.0 million, or $0.16 per share, compared with a GAAP net loss of $99.6 million in 2024 that included a large goodwill impairment. Non-GAAP net income was $122.3 million, with adjusted EBITDA of $186.5 million, down from $223.9 million.
Pacira repurchased 5.9 million shares in 2025 for $150.0 million, ending the year with 41.1 million shares outstanding and $150.0 million remaining under its authorization. For 2026, it guides to total revenue of $745–$770 million, EXPAREL sales of $600–$620 million and non-GAAP gross margin of 77–79%.
Pacira BioSciences, Inc. expanded its Board of Directors from nine to ten members and appointed Dr. Samit Hirawat as a Class III director, effective immediately on January 27, 2026. He will also serve on the Board’s Science and Technology Committee.
Dr. Hirawat will receive Pacira’s standard compensation for non-employee directors. The Board determined that he qualifies as an independent director under Nasdaq’s listing standards. The company later issued a press release on January 28, 2026 to publicly announce his appointment.
Pacira BioSciences, Inc. filed a current report stating that it has issued a press release with its preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2025. The company is sharing an early view of its 2025 revenue performance before final audited results are available.
The press release, dated January 8, 2026, is included as Exhibit 99.1. Pacira notes that this revenue information is being furnished rather than filed under securities laws, which limits how it is treated for certain liability and incorporation-by-reference purposes.
Pacira BioSciences, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The full text is included as Exhibit 99.1.
The company states the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed filed under the Exchange Act. PCRX common stock trades on the Nasdaq Global Select Market.
Pacira BioSciences (PCRX) filed an 8-K on 9 July 2025 announcing a restructuring under Item 2.05. The company is shuttering its first-generation 45-liter manufacturing suite at its San Diego Science Center after commissioning two 200-plus-liter suites (Swindon 2021, San Diego 2024) that produce roughly 4× more bulk EXPAREL per batch and carry a lower cost structure.
The decision triggers a reduction in force of 71 employees, or ~8 % of head-count. Management expects to book $2.4 – $2.8 million in cash charges for severance, garden leave and related benefits plus $5.4 million of accelerated depreciation, with most of the impact flowing through Q3 2025 results.
Once complete, Pacira anticipates an annual operating-expense reduction of about $13 million and improved gross margins for EXPAREL owing to higher yields and scale efficiencies. The company cautions that additional, presently unforeseen, charges may arise and reiterates standard forward-looking-statement language.
An employee communication from CEO Frank D. Lee (Exhibit 99.1) was furnished under Item 7.01 and is not deemed filed. No changes were disclosed to current revenue guidance, product strategy or other financial metrics beyond the charges and cost-saving estimates.